Alnuctamab + Mezigdomide for Multiple Myeloma

Phase 1

Waitlist Available

Research Sponsored by Celgene

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from first participant enrollment until the last participant is no longer evaluable for response, or has progressed or the last survival follow-up (up to approximately 5 years)

Awards & highlights

No Placebo-Only Group

Summary

"This trial aims to find out the right amount and timing to give alnuctamab along with mezigdomide to patients with relapsed or refractory multiple myeloma. The study will

Who is the study for?

This trial is for people with multiple myeloma that has come back or didn't respond to treatment. They should have tried at least three other treatments before joining Part A, and one to three prior treatments for Parts B and C. Those who've already taken alnuctamab or mezigdomide can't participate.

What is being tested?

The study is testing a combination of two drugs, Alnuctamab and Mezigdomide, along with Dexamethasone, in patients with relapsed/refractory multiple myeloma. It aims to find the best dose, schedule, safety profile, and early signs of effectiveness.

What are the potential side effects?

Possible side effects from Alnuctamab and Mezigdomide may include reactions at the infusion site, changes in blood counts leading to increased infection risk or bleeding problems, fatigue, nausea, and potential impacts on liver function.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from first participant enrollment until the last participant is no longer evaluable for response, or has progressed or the last survival follow-up (up to approximately 5 years)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from first participant enrollment until the last participant is no longer evaluable for response, or has progressed or the last survival follow-up (up to approximately 5 years)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from first participant enrollment until the last participant is no longer evaluable for response, or has progressed or the last survival follow-up (up to approximately 5 years) for reporting.